US 8,877,938 B2
Compounds Containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester Moieties and CationsGeneral
US 8,877,938 B2
Compounds Containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester Moieties and Cations
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Timothy Thomas
Art Unit:
1628 Organic Chemistry
Agent:
Matthew Mulkeen
Inventors:
Lili Feng; Sven Erik Godtfredsen; Bin Hu; Yugang Liu; Piotr Karpinski; Paul Allen Sutton; Mahavir Prashad; Michael J. Girgis; Thomas J. Blacklock
Assignee:
Priority:
11/08/06
Filed:
01/15/08
Granted:
11/04/14
Expiration:
05/28/26
Abstract
A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and/or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.
Cooperative Patent Classification (CPC)
A61A61P27/06A61K31/5415A61PC07D207/50C07C233/47C07D